AMARILLO, TX -- (MARKET WIRE) -- September 26, 2006 -- Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR), today announced that it has commenced an effort to raise up to $5 Million to complete clinical studies of its low-dose oral interferon. Successful completion of these studies is necessary for ABI to apply for FDA approval.
